FMS Price Prediction Next Week
Based on the recent analyst ratings and technical indicators, here's the analysis for FMS for the next trading week:
Technical Analysis
The RSI(14) reading of 58.98 indicates the stock is approaching but not yet in overbought territory, suggesting room for further upside. The MACD of 0.48 shows positive momentum. The stock is trading above both its 20-day SMA (23.79) and 200-day SMA (21.02), confirming a bullish trend.
Analyst Consensus Recent analyst actions show mixed sentiment:
- Warburg Research upgraded to Hold with €43.00 target
- J.P. Morgan maintained Sell with €37.30 target
- Kepler Capital maintained Hold with €47.00 target
The average analyst price target is €46.19, suggesting a -4.13% downside from current levels.
Price Projections for Next Week Based on Fibonacci levels:
- Resistance levels: $25.11 (R1), $25.39 (R2), $25.85 (R3)
- Support levels: $24.19 (S1), $23.91 (S2), $23.45 (S3)
- Pivot point: $24.65
Trading Recommendation SELL at current levels with:
- Entry: $24.65 (pivot point)
- Stop loss: $25.39 (R2)
- Target: $23.91 (S2)
Rationale:
- Multiple analysts have issued Hold/Sell ratings with price targets below current levels
- Technical indicators suggest the stock is approaching resistance levels
- Fibonacci projections indicate more downside potential than upside
The stock is likely to face resistance around $25.39 level, with potential downside to $23.91 in the coming week based on technical setup and analyst sentiment.
FMS Similar Chart Price Prediction
The price of FMS is predicted to go up 0.49%, based on the high correlation periods with WDAY. The similarity of these two price pattern on the periods is 98.69%.
FMS
WDAY
Up: 0.49%Similarity: 98.69%
FMS Revenue Forecast
FMS EPS Forecast
FMS FAQs
What is bull’s view on FMS?
What is bear's view on FMS?
What is FMS revenue forecast for next quarter？
What is FMS eps forecast for next quarter？
FMS VS S&P500
Diversified by geography and business mix, Fresenius should be able to benefit from ongoing growth in treating ESRD patients worldwide once the pandemic recedes.
Increasing at-home treatment rates could raise demand for the company's at-home systems and boost how long patients can continue to work and stay on commercial insurance plans, which can positively affect the company's profitability.
Through its venture capital arm, Fresenius is investing in new ways to treat ESRD patients, aside from more traditional dialysis tools, which could help keep it at the forefront of this market.
FMS Analyst's Forecast
David Macdonald
Truist Securities
Hold
2025-01-06
Price Target
$23 → $25
Upside
+9.65%
Truist raised the firm's price target on Fresenius Medical to $25 from $23 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 for Healthcare Services. The firm sees the outlook for the group as "mixed", with bullish stance on the underlying demand drivers and overarching sector tailwinds that include demographics, value-based care, and core demand being offset by heightened concern around a likely more cost focused government backdrop. Selectivity is key and cash flow generation with broadly attractive financial flexibility are set to provide solid support, while the recent valuation re-rating for several names provides a better setup around risk/reward, the analyst tells investors in a research note.
David Macdonald
Truist Securities
Hold
2024-10-07
Price Target
$22 → $23
Upside
+11.7%
